Indian Journal of Pharmacy & Drugs Studies https://mansapublishers.com/index.php/ijpds <pre><strong>Discipline:</strong> Pharmaceutical Sciences <br /><strong>Starting Year:</strong> 2020 <br /><strong>Current volume:</strong> Volume 4<br /><strong>Issue per year:</strong> 4 issues<br /><strong>Indexing: </strong>Google Scholar<br /><strong>E-mail: <a href="mailto:editor.ijpds@mansapublishers.com" target="_blank" rel="noopener">editor.ijpds@mansapublishers.com</a> </strong></pre> Mansa STM publishers en-US Indian Journal of Pharmacy & Drugs Studies Medication Reconciliation - A patient safety strategy https://mansapublishers.com/index.php/ijpds/article/view/3688 <p>Patient safety is an international concern and mandates the attention of healthcare professionals. Recently, it has been recognized that multiple strategies and members of the healthcare team from the treating physician to the dispensing pharmacist have a key role to play in assuring patient safety. One such role is that of the clinical pharmacist and the medication reconciliation conducted by them. It is done to get a thorough understanding of the patient medical history, medication history, drug allergy history and many others that could be a loophole for patient harm. This review summarizes a brief review about what is patient safety, and the patterns of employing medication reconciliation in different clinical scenarios that is the emergency department, in transitions of care and in geriatric care. It is specifically important to address the role of growing technology in the same field and so we have also enlisted the ongoing efforts done in the same domain. This review also addresses the role of clinical pharmacists and their emerging responsibility in maintaining a patient safety culture.</p> Janice Jacson Mandumpala Copyright (c) 2022 Janice Jacson Mandumpala http://creativecommons.org/licenses/by-nc-nd/4.0 2022-11-03 2022-11-03 116 120 Comprehensive analysis and critical review of randomized clinical trials on safety profiling of Hydroxychloroquine and Belimumab https://mansapublishers.com/index.php/ijpds/article/view/3747 <p>Systemic Lupus Erythematosus (SLE), an autoimmune disorder is characterized by multiorgan damage, flares, and heterogeneity in its clinical symptoms. The treatment strategy for this notorious disease focuses on long-term anti-SLE treatment to improve the quality of life, prevent flares, and suppress the immune system. Thus, the chronic use of SLE medicines makes it inevitable to study the safety and tolerability of drugs in large populations. In this comprehensive-analytical study, Hydroxychloroquine (HCQ), which is known for its safe use in SLE, and Belimumab, which is comparatively a novel monoclonal antibody were critically analyzed for their adverse events. We performed the absolute risk, relative risk ratio, and odds ratio analysis after critically scrutinizing the clinical trials for significant adverse effects. HCQ showed major effects on the eye and heart. However, based on the results, HCQ was found to be safer than Belimumab, as a few serious complications were found associated with Belimumab. Our results were found to be as per the previous meta-analysis. This comprehensive review is aimed at analyzing the safety profiles of two widely used drugs for SLE I-e HCQ and Belimumab. We have conducted this review, critical analysis was done to critically analyze the clinical trials, and to gather the information of interest from these trials. Both anti-SLE drugs; HCQ and Belimumab were found to be safe for use against SLE. But comparatively, HCQ showed a safer profile than Belimumab which can be attributed to HCQ’s long-term history of use since 1955. The observation emphasized the researchers for further clinical trials with a more standardized approach, specifically for Belimumab to determine its safety and tolerability in the post-marketing stage.</p> Zahra Maryam Ausaf Ahmad Copyright (c) 2023 Zahra Maryam, Ausaf Ahmad http://creativecommons.org/licenses/by-nc-nd/4.0 2023-01-01 2023-01-01 121 127 Advanced UV Spectrophotometric Method Development and Validation for Simultaneous Estimation of Azelnidipine and Telmisartan in Pharmaceutical Dosage Form https://mansapublishers.com/index.php/ijpds/article/view/3602 <p>The presented research work aims to develop and validate three advanced UV spectrophotometric methods for the simultaneous estimation of Azelnidipine (AZL) and Telmisartan (TEL). These methods offer a higher degree of sensitivity than already-existing methods of analysis. By implementing advanced spectroscopic techniques such as the simultaneous method, Q-ratio method, and first derivative spectroscopy method. These methods offer a higher degree of sensitivity than already-existing methods of analysis. by implementing advanced spectroscopic techniques such as the simultaneous method, Q-ratio method, and first derivative spectroscopy method. The linearity of the three methods was in the range of 2 μg/ml to 12 μg/ml for AZL and 10 μg/ml to 50 μg/ml for TEL. The correlation coefficients for simultaneous estimation were 0.999 and 0.998 for AZL and TEL, respectively, and 0.9992 and 0.9989 for AZL and TEL, respectively, for the first derivative method, whereas the correlation coefficients for the Q-ratio method were 0.999 and 0.9988, respectively. The LOD values obtained by the simultaneous estimation method were found to be lower as compared to those obtained by the first derivative method and the Q-ratio method, proving that the sensitivity of the simultaneous estimation method is high.</p> Pallavi Suthar Rajashree Mashru Copyright (c) 2022 Pallavi Suthar, Rajashree Mashru http://creativecommons.org/licenses/by-nc-nd/4.0 2022-12-17 2022-12-17 128 134